Key result
Rheumatic heart disease mortality falls ~3% annually, diverging from non-rheumatic valvular disease.
Why the study?
Valvular heart disease in the Middle East and North Africa (MENA) region reflects two distinct processes: rheumatic heart disease tied to poverty and untreated streptococcal infection, and non-rheumatic valvular heart disease linked to population aging and metabolic risk, motivating a regional comparison of their disease burdens from 1990 to 2023.
Do the epidemiological trajectories (mortality, incidence, and prevalence) of rheumatic heart disease and non-rheumatic valvular heart disease diverge across the 21 countries of the MENA region from 1990 to 2023?
Observational
Yes
Do the epidemiological trajectories (mortality, incidence, and prevalence) of rheumatic heart disease and non-rheumatic valvular heart disease diverge across the 21 countries of the MENA region from 1990 to 2023?
Answers are grounded in this paper and cite their sources.
In the MENA region from 1990 to 2023, RHD mortality declined while its incidence and absolute prevalence continued to rise, whereas NRVHD showed a more than threefold expansion in prevalent cases and nearly tripled absolute deaths, necessitating dual public health investments in primary streptococcal prevention and structural heart care capacity.
Background and Aims Valvular heart disease in the Middle East and North Africa (MENA) region reflects two distinct processes. Rheumatic heart disease (RHD), which is tied to poverty and untreated streptococcal infection, and non‐rheumatic valvular heart disease (NRVHD), which is linked to population aging and metabolic risk. This study compared the burden of both conditions across the region from 1990 to 2023. Methods Age‐standardized mortality, incidence, and prevalence rates per 100,000 population were obtained from the Global Burden of Disease database for 21 MENA countries. Joinpoint regression estimated the average annual percentage change (AAPC), pairwise comparison tested whether the two conditions diverged, and mortality was projected through 2050. Results RHD mortality fell from 5.87 to 2.19 per 100,000 (AAPC −2.97%), despite a slight increase in incidence and a doubling of prevalent cases to 3.36 million. In contrast, NRVHD mortality rates remained stable while absolute deaths nearly tripled, accompanied by steady increases in incidence and prevalence, with prevalent cases more than tripling to 557,576. Women carried a higher RHD burden, whereas men accounted for the greater increase in NRVHD burden. The temporal trends for RHD and NRVHD were statistically distinct across all outcomes. By 2050, RHD mortality is projected to decline by approximately 51%, compared with a 2.9% decline in NRVHD mortality. Conclusion RHD and NRVHD exhibit contrasting trajectories across the MENA region, reflecting differences in their underlying epidemiology. These patterns call for distinct public health strategies, with greater emphasis on primary prevention of RHD and expansion of diagnostic and surgical capacity for NRVHD.
No takes yet. Share an insight, caveat, or question.
Al-Harbi et al. (2026) conducted an observational in Rheumatic heart disease (RHD) and non-rheumatic valvular heart disease (NRVHD). Rheumatic heart disease (RHD) vs. Non-rheumatic valvular heart disease (NRVHD) was evaluated on Age-standardized mortality rate (ASMR) average annual percentage change (AAPC) from 1990 to 2023 (95% CI -3.17 to -2.78, p=<0.001). Rheumatic heart disease age-standardized mortality declined from 5.87 to 2.19 per 100,000, diverging from non-rheumatic valvular heart disease mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: